As bidding ends today for three IPOs, Indo-MIM tops the grey market premium chart with an estimated 39% listing gain. Xtranet Technologies and Lohia Corp trail far behind with modest 7% and 1.65% gains respectively. Investors have only a few hours left to place their bids.

Key Takeaways

  • Indo‑MIM GMP at ₹190, ~39% expected listing gain
  • Xtranet Technologies GMP at ₹9, ~7% expected listing gain
  • Lohia Corp GMP at ₹7, ~1.65% expected listing gain

Three IPOs Near Bidding Deadline

Indo‑MIM, Xtranet Technologies, and Lohia Corp are closing their subscription windows today, giving investors a final chance to bid. Though each operates in distinct sectors—Indo‑MIM in metal‑injection molding, Xtranet in IT services, and Lohia in plastic‑processing machinery—the grey market premium (GMP) clearly positions Indo‑MIM as the front‑runner.

Historical Background

The grey market premium is an unofficial metric that reflects investor sentiment before an IPO lists on the exchange. Historically, a high GMP has correlated with strong subscription levels and a post‑listing price premium, making it a valuable early‑stage indicator for traders.

IPO Specifics

Indo‑MIM is priced between ₹461‑₹485 per share and currently trades at a GMP of ₹190, implying an estimated listing price of around ₹675 – roughly a 39% upside. Xtranet Technologies is priced up to ₹127, with a modest GMP of ₹9, suggesting a listing price near ₹136 and a 7% gain. Lohia Corp is priced ₹404‑₹425, carries a GMP of only ₹7, and is expected to list around ₹432, delivering about a 1.65% gain.

Why This Matters

BozokMedia analysis shows that a high GMP not only reflects strong retail enthusiasm but also signals potential institutional backing, which can drive post‑listing price stability. Consequently, Indo‑MIM’s superior GMP makes it the most enticing prospect for short‑term investors.

"GMP often serves as the most reliable barometer of true IPO demand," says financial analyst Rajesh Kumar.
Did You Know?: Indo‑MIM pioneered India’s first metal‑injection‑molding technology in 1996, now serving automotive, defence, and aerospace sectors globally.

Frequently Asked Questions

Is it safe to invest solely based on GMP?
No. Investors should also assess the company’s financial health, business model, and valuation.

What should investors do after bidding closes?
They should confirm their order with their broker and stay informed about any last‑minute market movements.